Loading

Important Safety Information

This therapy is not for everyone. Please consult your physician. A prescription is required. For more information, please call Medtronic at (877) 526-7890.

 


Resolute Integrity Coronary Stent System

Intended Use

The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.20 mm.


Contraindications

The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is contraindicated for use in: • Patients with a known hypersensitivity or allergies to aspirin, heparin, bivalirudin, clopidogrel, prasugrel, ticagrelor, ticlopidine, drugs such as zotarolimus, tacrolimus, sirolimus, everolimus or similar drugs or any other analogue or derivative • Patients with a known hypersensitivity to the cobalt-based alloy (cobalt, nickel, chromium and molybdenum) • Patients with a known hypersensitivity to the BioLinx® polymer or its individual components

Coronary artery stenting is contraindicated for use in: • Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated • Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system


Warnings

• Please ensure that the inner package has not been opened or damaged as this would indicate the sterile barrier has been breached. • The use of this product carries the same risks associated with coronary artery stent implantation procedures, which include subacute and late vessel thrombosis, vascular complications and/or bleeding events. • This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy.


Precautions

• Only physicians who have received adequate training should perform implantation of the stent. • Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed. • Subsequent stent restenosis or occlusion may require repeat catheter-based treatments (including balloon dilatation) of the arterial segment containing the stent. The long-term outcome following repeat catheter-based treatments of previously implanted endothelialized stents is not well characterized. • The risks and benefits of the stent implantation should be assessed for patients with a history of severe reaction to contrast agents. • Do not expose or wipe the product with organic solvents such as alcohol. • When drug-eluting stents (DES) are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the RESOLUTE pivotal clinical trials. • Compared to use within the specified Indications for Use, the use of DES in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, myocardial infarction (MI), or death • Care should be taken to control the position of the guide catheter tip during stent delivery, deployment, and balloon withdrawal. Before withdrawing the stent delivery system, visually confirm complete balloon deflation by fluoroscopy to avoid guiding catheter movement into the vessel and subsequent arterial damage • Stent thrombosis is a low-frequency event that is frequently associated with MI or death. Data from the RESOLUTE clinical trials have been prospectively evaluated and adjudicated using the definition developed by the Academic Research Consortium (ARC).

The safety and effectiveness of the Resolute Integrity stent have not yet been established in the following patient populations: • Patients with target lesions which were treated with prior brachytherapy or the use of brachytherapy to treat in-stent restenosis of a Resolute Integrity stent • Women who are pregnant or lactating • Men intending to father children • Pediatric patients • Patients with coronary artery reference vessel diameters of <2.25 mm or >4.20 mm • Patients with coronary artery lesions longer than 27 mm or requiring more than one Resolute Integrity stent • Patients with evidence of an acute MI within 72 hours of intended stent implantation • Patients with vessel thrombus at the lesion site • Patients with lesions located in a saphenous vein graft, in the left main coronary artery, ostial lesions, or bifurcation lesions • Patients with diffuse disease or poor flow distal too identified lesions • Patients with tortuous vessels in the region of the target vessel or proximal to the lesion • Patients with in-stent restenosis • Patients with moderate or severe lesion calcification at the target lesion • Patients with occluded target lesions including chronic total occlusions • Patients with three-vessel disease • Patients with a left ventricular ejection fraction of <30% • Patients with a serum creatinine of >2.5mg/dl • Patients with longer than 24 months of follow-up

The safety and effectiveness of the Resolute Integrity stent have not been established in the cerebral, carotid or peripheral vasculature.


Potential Adverse Events

Other risks associated with using this device are those associated with percutaneous coronary diagnostic (including angiography and IVUS) and treatment procedures. These risks (in alphabetical order) may include but are not limited to: • Abrupt vessel closure • Access site pain, hematoma or hemorrhage • Allergic reaction (to contrast, antiplatelet therapy, stent material, or drug and polymer coating) • Aneurysm, pseudoaneurysm, or arteriovenous fistula (AVF) • Arrhythmias, including ventricular fibrillation • Balloon rupture • Bleeding • Cardiac tamponade • Coronary artery occlusion, perforation, rupture or dissection • Coronary artery spasm • Death • Embolism (air, tissue, device or thrombus) • Emergency surgery: peripheral vascular or coronary bypass • Failure to deliver the stent • Hemorrhage requiring transfusion • Hypotension/hypertension • Incomplete stent apposition • Infection or fever • MI • Pericarditis • Peripheral ischemia/peripheral nerve injury • Renal failure • Restenosis of the stented artery • Shock/pulmonary edema • Stable or unstable angina • Stent deformation, collapse, or fracture • Stent migration (or embolization) • Stent misplacement • Stroke/transient ischemic attack • Thrombosis (acute, subacute or late)


Adverse Events Related to Zotarolimus

Patients' exposure to zotarolimus is directly related to the total amount of stent length implanted. The actual side effects/complications that may be associated with the use of zotarolimus are not fully known. The adverse events that have been associated with the intravenous injection of zotarolimus in humans include but are not limited to: • Anemia • Diarrhea • Dry skin • Headache • Hematuria • Infection • Injection site reaction • Pain (abdominal, arthralgia, injection site) • Rash

Please reference appropriate product Instructions for Use for more information regarding indications, warnings, precautions and potential adverse events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.


 

 


Integrity® Coronary Stent System

Intended Use

The Integrity Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo or restenotic lesions with reference vessel diameters of 2.25–4.0 mm and ≤30 mm in length using direct stenting or predilatation.

Contraindications

  • Patients in whom antiplatelet and/or anticoagulation therapy is contraindicated
  • Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of a stent or stent delivery system


Warnings/Precautions

  • The long-term effects of stents and the risks associated with lifelong carrying of these implants are unknown. This lack of knowledge should be considered in making a risk/ benefit assessment for the patient prior to implantation.
  • The Integrity Coronary Stent Systems are provided sterile, for one procedure only. Do not resterilize. Use by the “Use by” date noted on the package.
  • Only physicians who have received appropriate training should perform implantation of the stent. Use of an Integrity Coronary Stent System requires advanced coronary angioplasty technical skills. The instructions will give technical guidance, but do not obviate the need for formal training in the use of the device.
  • Patients allergic to cobalt alloy may suffer an allergic reaction to this implant.
  • Do not remove the stent from the stent delivery system; the stent cannot be removed and placed on another balloon catheter for deployment.
  • Do not try to straighten a kinked shaft or hypotube. Straightening a kinked metal shaft may result in breakage of the shaft. If the device is kinked, it should not be used.
  • Significant amounts of air in the balloon may cause uneven expansion of the stent and difficulty in deployment of the stent. Do not pre-inflate balloon prior to stent deployment. Use balloon preparation technique described within this instructional material.
  • The Integrity Coronary Stent Systems do not provide for distal dye injections or pressure measurements through the guidewire lumen.
  • Expansion of the stent should not be undertaken if the stent is not appropriately positioned in the vessel. If the position of the stent is not optimal, it should not be expanded.
  • Incomplete deployment of the stent (i.e., stent not fully expanded) may cause procedural complications resulting in patient injury.
  • Advancement of an Integrity Coronary Stent System through a previously stented segment may cause procedural complications resulting in patient injury.
  • Placement of the stent has the potential to compromise sidebranch patency.
  • Administer appropriate anticoagulant/ antiplatelet and coronary artery vasodilator therapy according to current medical guidelines and manufacturer’s instructions.
  • Caution must be taken when using ancillary equipment, such as intravascular ultrasound catheters, to avoid dislodgement or deformation of the stent.
  • When multiple stents are required, stent materials should be of similar composition. Placing multiple stents of different materials in contact with each other may increase the potential for corrosion. Data obtained from in vitro corrosion tests using a cobalt alloy stent (Medtronic Integrity Coronary Stent) in combination with a stainless steel alloy stent (Boston Scientific Liberté® Coronary Stent) do not suggest an increased risk of in vivo corrosion.
  • When using two wires, care should be taken when introducing, torquing and removing one or both guidewires to avoid entanglement. It is recommended that one guidewire be completely withdrawn from the patient before removing any additional equipment.
  • Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed.
  • Judicious selection of patients is necessary since the use of this device carries the associated risk of subacute thrombosis, vascular complications and/or bleeding events. Administration of appropriate anticoagulant, antiplatelet and coronary vasodilator therapy is critical to successful stent implantation and follow-up.
  • Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. The long-term outcome following repeat dilatation of endothelialized coronary stents is unknown at present.


Potential Adverse Events

The following complications may be associated with the use of coronary stenting devices or PTCA:

  • Acute myocardial infarction
  • Allergic reaction to contrast medium/stent material/ medications
  • Arrhythmias (including ventricular fibrillation and ventricular tachycardia)
  • Arteriovenous fistula
  • Bleeding complications
  • Cardiac tamponade
  • Cerebrovascular accident/stroke
  • Death
  • Dissection of coronary artery
  • Drug reactions
  • Embolization (air, stent, tissue or thrombotic)
  • Emergency coronary artery bypass graft surgery (CABG)
  • Endocarditis
  • Failure to deliver the stent
  • Stent deformation, collapse or fracture
  • Hematoma
  • Hemorrhage requiring transfusion
  • Injury of the coronary artery
  • Myocardial ischemia/infarction
  • Pain and tenderness at the insertion site
  • Perforation
  • Peripheral Ischemia
  • Peripheral nerve injury
  • Pseudoaneurysm (coronary/ femoral/radial)
  • Pyrogenic reaction
  • Restenosis of the dilated artery or stented segment
  • Sepsis/infection
  • Short-term hemodynamic deterioration (hypotension/ hypertension)
  • Stent thrombosis or occlusion
  • Total occlusion of coronary artery
  • Unstable angina
  • Vascular thrombosis
  • Vessel dissection/perforation/spasm


Please reference appropriate product Instructions for Use for a more detailed list of indications, warnings, precautions and potential adverse events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.


 

 


Medtronic Vascular Endeavor Zotarolimus-Eluting Coronary Stent on the Over-the-Wire (OTW) or Multi-Exchange II (MX2) Stent Delivery Systems

For complete Endeavor Instructions For Use, including Pre- and Post-Procedure Antiplatelet Regimen please download Instructions For Use (IFU) document

Indications

The Endeavor® Zotarolimus-Eluting Coronary Stent on the Over-the-Wire (OTW) or Multi-Exchange® II (MX2) Stent Delivery System is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo lesions of length ≤27 mm in native coronary arteries with reference vessel diameters of ≥2.5 mm to ≤3.5 mm.

Contraindications

The Endeavor Zotarolimus-Eluting Coronary Stent System is contraindicated for use in:

  • Patients with a known hypersensitivity to zotarolimus or structurally-related compounds
  • Patients with a known hypersensitivity to the cobalt-based alloy (cobalt, nickel, chromium, and molybdenum) 
  • Patients with a known hypersensitivity to Phosphorylcholine polymer or its individual components.

Coronary artery stenting is contraindicated for use in:

  • Patients who cannot receive recommended antiplatelet and/or anticoagulation therapy  
  • Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the stent or stent delivery system

Warnings

  • Please ensure that the inner package has not been opened or damaged, as this indicates the sterile barrier has been breached
  • The use of this product carries the risks associated with coronary artery stenting, including subacute thrombosis, vascular complications, and/or bleeding events
  • This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy
  • During guidewire exchange, the wire should be manipulated while under high-quality fluoroscopic observation. Failure to do so may result in the wire moving into the vessel resulting in damage to the vessel wall.

Precautions

  • Only physicians who have received adequate training should perform implantation of the stent
  • Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed 
  • Subsequent stent blockage may require repeat dilatation of the arterial segment containing the stent. The long-term outcome following repeat dilatation of endothelialized stents is not well characterized
  • Risks and benefits of the stent should be assessed for patients with history of severe reaction to contrast agents
  •  Do not expose or wipe the product with organic solvents such as alcohol or detergents
  • Stent thrombosis is a low-frequency event that current drug-eluting stent (DES) clinical trials are not adequately powered to fully characterize. Stent thrombosis is frequently associated with myocardial infarction (MI) or death. Data from the ENDEAVOR randomized clinical trials have been prospectively evaluated and adjudicated using both the protocol definition of stent thrombosis and the definition developed by the Academic Research Consortium (ARC), and demonstrate specific patterns of stent thrombosis that vary depending on the definition used. In the ENDEAVOR clinical trials analyzed to date, the differences in the incidence of stent thrombosis observed with the Endeavor stent compared to bare metal stents have not been associated with an increased risk of cardiac death, MI, or all-cause mortality. Additional data from longer-term follow-up in the ENDEAVOR randomized clinical trials and analyses of DES-related stent thrombosis are expected and should be considered in making treatment decisions as data become available 
  • When DES are used outside the specified Indications for Use, patient outcomes may differ from the results observed in the pivotal clinical trials
  • Compared to use within the specified Indications for Use, the use of DES in patients and lesions outside of the labeled indications, including more tortuous anatomy, may have an increased risk of adverse events, including stent thrombosis, stent embolization, MI, or death.
     

The safety and effectiveness of the Endeavor stent have not yet been established in the following patient populations:

  • Women who are pregnant or lactating 
  • Men intending to father children 
  • Pediatric patients
  • Patients with vessel thrombus at the lesion site 
  • Patients with coronary artery reference vessel diameters <2.5 mm or >3.5 mm 
  • Patients with coronary artery lesions longer than 27 mm or requiring more than one Endeavor stent 
  • Patients with lesions located in saphenous vein grafts, in the unprotected left main coronary artery, ostial lesions, or lesions located at a bifurcation
  • Patients with diffuse disease or poor flow distal to the identified lesions 
  • Patients with multivessel disease
  • Patients with tortuous vessels in the region of the obstruction or proximal to the lesion 
  • Patients with a recent acute myocardial infarction where there is evidence of thrombus or poor flow 
  • Patients for longer than 48 months of follow-up
  • Patients with in-stent restenosis
  • Patients with moderate or severe calcification in the lesion or a chronic total occlusion
  • Patients with prior brachytherapy of the target lesion or the use of brachytherapy to treat in-stent restenosis in an Endeavor stent.

The safety and effectiveness of the Endeavor stent have not been established in the cerebral, carotid, or peripheral vasculature.

Potential Adverse Events

Other risks associated with using this device are those associated with percutaneous coronary diagnostic (including angiography and IVUS) and treatment procedures. These risks may include, but are not limited to

  • Abrupt vessel closure
  • Access site pain, hematoma or hemorrhage
  • Allergic reaction (to contrast, antiplatelet therapy, stent material, or drug and polymer coating)
  • Aneurysm, pseudoaneurysm, or arteriovenous fistula (AVF)
  • Arrhythmias
  • Balloon rupture
  • Cardiac tamponade
  • Coronary artery occlusion, perforation, rupture, or dissection
  • Coronary artery spasm
  • Death
  • Embolism (air, tissue, device, or thrombus)
  • Emergency surgery: peripheral vascular or coronary bypass
  • Failure to deliver the stent
  • Hemorrhage requiring transfusion
  • Hypotension/hypertension
  • Incomplete stent apposition
  • Infection or fever
  • Late or very late thrombosis
  • Myocardial infarction (MI)
  • Myocardial ischemia
  • Peripheral ischemia/peripheral nerve injury
  • Renal failure
  • Restenosis of the stented artery
  • Rupture of native or bypass graft
  • Shock/pulmonary edema
  • Stent deformation, collapse, or fracture
  • Stent migration
  • Stent misplacement
  • Stroke/transient ischemic attack
  • Thrombosis (acute and subacute) 
  • Unstable angina
  • Ventricular fibrillation.
     

Adverse Events Related to Zotarolimus

Patients' exposure to zotarolimus is directly related to the total amount of stent length implanted. The actual side effects/complications that may be associated with the use of zotarolimus are not fully known. The adverse events that have been associated with the intravenous injection of zotarolimus in humans include

  • Anemia
  • Application site reaction
  • Diarrhea
  • Dry skin
  • Headache
  • Hematuria
  • Infection
  • Injection site reaction
  • Pain (abdominal, arthralgia, injection site)
  • Rash.

Please reference appropriate product Instructions for Use for more information regarding indications, warnings, precautions and potential adverse events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

 

 


Driver® Coronary Stent System

Intended Use

  • The Medtronic Driver MX2/Over-the-Wire Coronary Stent Delivery Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo or restenotic lesions with reference vessel diameters of 3.0 mm to 4.0 mm and ≤30 mm in length using direct stenting or predilatation.

Contraindications

  • Patients in whom antiplatelet and/or anticoagulation therapy is
    contraindicated.
  • Patients who are judged to have a lesion that prevents complete inflation of an angioplasty balloon.

Warnings/Precautions

  • Judicious selection of patients is necessary since the use of this device carries the associated risk of subacute thrombosis, vascular complications and/or bleeding events. Administration of appropriate anticoagulant, antiplatelet and coronary vasodilator therapy is critical to successful stent implantation and follow-up.
  • Patients allergic to F-562 cobalt-chromium alloy may suffer an allergic reaction to this implant.
  • Only physicians who have received appropriate training should perform implantation of the stent.
  • Stent placement should only be performed at hospitals where emergency coronary artery bypass graft surgery can be readily performed.
  • Subsequent restenosis may require repeat dilatation of the arterial segment containing the stent. The long-term outcome following repeat dilatation of endothelialized coronary stents is unknown at present.
  • When multiple stents are required, stent materials should be of similar composition. Placing multiple stents of different materials in contact with each other may increase the potential for corrosion. Data obtained from in vitro corrosion tests using a F562 CoCr alloy stent (Medtronic Driver Coronary Stent) in combination with a 316L stainless steel alloy stent (Medtronic S7 Coronary Stent) do not suggest an increased risk of in vivo corrosion.
  • If the physician encounters difficulty while trying to cross the lesion by direct stenting and determines the lesion to be uncrossable, this patient should be treated per predilatation practice. The stent (the same stent if undamaged) or a new stent of the same kind should then be advanced and deployed with predilatation.
  • Implanting a stent may lead to dissection of the vessel distal and/or proximal to the stented portion and may cause acute closure of the vessel requiring additional intervention (e.g., CABG, further dilatation, placement of additional stents or other).
  • Outcomes (beyond 270 days) for this permanent implant are unknown at present.

Adverse Events

  • Potential adverse events that may be associated with the use of a coronary stent in native coronary arteries (including those listed in the Driver Instructions for Use) are death, myocardial infarction, emergency coronary artery bypass graft surgery (CABG), stent thrombosis, bleeding complications, stroke/cerebrovascular accidents, vascular complications, stent failures, acute myocardial infarction, myocardial ischemia, arrhythmias (including ventricular fibrillation and ventricular tachycardia dissection), distal emboli (air, tissue or thrombotic emboli), hemorrhage requiring transfusion, perforation, restenosis of stented segments, stent embolization, total occlusion of coronary artery, cardiac tamponade, femoral pseudoaneurysm, spasm, hypotension/ hypertension, allergic reaction to drugs/contrast medium/stent material, peripheral ischemia, peripheral nerve injury, infection and pain at the insertion site, and hematoma.

Please reference appropriate product Instructions for Use for a more detailed list of indications, warnings, precautions and potential adverse events.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician.

For further information, please call Medtronic at 1-888-283-7868.


 

Last updated: 12 Sep 2012

Section Navigation

Additional information

Contact Us

Medtronic
Medtronic CardioVascular
work (877) 526-7890
work International:
(763) 526-7890